TLDR The document concludes that alopecia has various forms, each with specific treatments, but no definitive cure for certain types like CCCA has been proven.
The 2018 document provides a comprehensive overview of alopecia, classifying it into scarring and nonscarring types, and highlighting the importance of patient history and physical examination for diagnosis. It details androgenic alopecia, the most common form, affecting 50% of men and women by age 50, with treatments including finasteride, minoxidil, and antiandrogenic agents. Telogen effluvium, a stress-related diffuse hair loss, and trichotillomania, a compulsive hair-pulling disorder, are also discussed with their respective treatments. The document covers other forms such as traction alopecia, alopecia areata, tinea capitis, and lupus erythematosus-related alopecia, each with specific clinical features and treatments. Central Centrifugal Cicatricial Alopecia (CCCA) is described as a scarring alopecia primarily affecting African American women, with treatments like corticosteroids and tetracyclines, but no definitive treatment to alter its progression has been proven in controlled clinical trials.
125 citations,
May 2010 in “Pediatric dermatology” Systemic treatment is necessary for tinea capitis in children, with griseofulvin preferred for Microsporum infections.
391 citations,
January 2010 in “Journal of The American Academy of Dermatology” Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.
244 citations,
January 2010 in “Journal of the American Academy of Dermatology” The document says current treatments for alopecia areata do not cure or prevent it, and it's hard to judge their effectiveness due to spontaneous remission and lack of studies.
212 citations,
September 2008 in “Journal of The American Academy of Dermatology” Minoxidil and finasteride treat hair loss in men, while minoxidil treats hair loss in women.
94 citations,
September 2008 in “Journal of the American Academy of Dermatology” Traction alopecia is more common in African women than girls, especially when traction is applied to chemically relaxed hair; avoiding such hairstyles may reduce the risk.
72 citations,
July 2008 in “Dermatologic Therapy” CCCA is a scarring hair loss condition mainly in African descent women, possibly caused by genetics and hairstyling, treated with gentle hair care and medications.
6 citations,
May 2006 in “Skinmed” Androgens contribute to common male hair loss; more research needed for hair growth medication.
269 citations,
August 2002 in “Journal of The American Academy of Dermatology” 5% minoxidil works better for hair growth and density, with minor irritation.
234 citations,
December 1996 in “Journal of The American Academy of Dermatology” Middle-aged women with chronic telogen effluvium experience increased hair shedding but usually don't get significantly thinner hair.
28 citations,
September 1998 in “Medical Clinics of North America” Most hair loss can be diagnosed with patient history and physical exam, and a few common types make up most cases.
10 citations,
June 2000 in “Primary Care” The document explains different hair loss types and treatments, emphasizing diagnosis through examination and tests, and specific treatments for each condition.
1 citations,
October 2008 in “Expert Review of Dermatology” Frontal Fibrosing Alopecia is a slowly progressing hair loss condition, likely underdiagnosed, with ineffective treatments, needing more research to understand it fully.
January 2020 in “Der Pharmacia Lettre” Nanoparticle-based herbal remedies could be promising for treating hair loss with fewer side effects and lower cost, but more research is needed.
1 citations,
July 2018 in “Elsevier eBooks” Many treatments for hair loss show potential, but more testing is needed to confirm their effectiveness. Only minoxidil for women and minoxidil and finasteride for men are FDA approved.
